@article{c54c14d69b58449390f02e53bd3e843e,
title = "Disrupted relationship between blood glucose and brain dopamine D2/3 receptor binding in patients with first-episode schizophrenia",
keywords = "(+)-[C]-PHNO, Dopamine, Glucose, Psychosis, BASE-LINE, TOLERANCE, METABOLIC DYSREGULATION, D-2 RECEPTORS, (+)-[C-11]-PHNO, INSULIN, POSITRON-EMISSION-TOMOGRAPHY, PHARMACOLOGY, MORTALITY GAP, ENDOGENOUS DOPAMINE, ASSOCIATION",
author = "U. Sauerzopf and A. Weidenauer and I. Dajic and M. Bauer and L. Bartova and B. Meyer and L. Nics and C. Philippe and S. Pfaff and V. Pichler and M. Mitterhauser and W. Wadsak and M. Hacker and S. Kasper and R. Lanzenberger and L. Pezawas and N. Praschak-Rieder and M. Willeit",
note = "Funding Information: This project was funded by the Vienna Science and Technology Fund (WWTF, Grant number: CS15-033), the Austrian Science Fund (FWF, Grant number: P23585-B09), the Anniversary Fund of the Austrian National Bank (Grant number. 16723), the Medical Scientific Fund of the Mayor of the City of Vienna (Grant number 15189), all granted to M.W. Funding Information: Without relevance to this work, M. Willeit declares to having received speaker honoraria and consulting fees from Janssen-Cilag Pharma GmbH, Austria. Without relevance to this work, W. Wadsak declares to havingreceived speaker honoraria from GE Healthcare, research grants from IpsenPharma, Eckert-Ziegler AG, Scintomics and ITG. WW is a part time eployee ofCBmed Ltd (Center for Biomarker Research in Medicine, Graz, Austria). and is a member of advisory boards of Amgen, Chieri and Sanofi-Aventis. M. Hacker received consulting fees and/or honoraria from Bayer Healthcare BMS, Eli Lilly, EZAG, GE Healthcare, Ipsen, ITM, Janssen, Roche, Siemens Healthineers. R. Lanzenberger received travel grants and/or conference speaker honoraria within the last three years from Bruker BioSpin MR, Heel, and support from Siemens Healthcare regarding clinical research using PET/MR. He is a shareholder of the start-up company BM Health GmbH since 2019. S. Kasper received grants/research support, consulting fees and/or honoraria within the last three years from Angelini, AOP OrphanPharmaceuticals AG, Celegne GmbH, Eli Lilly, Janssen-Cilag Pharma GmbH, KRKA-Pharma, Lundbeck A/S, Mundipharma, Neuraxpharm, Pfizer, Sanofi, Schwabe, Servier, Shire, Sumitomo Dainippon Pharma Co. Ltd. and Takeda. U. Sauerzopf, A. Weidenauer, I. Dajic, M. Bauer, L. Bartova, B. Meyer, L. Nics, C. Philippe, S. Pfaff, V. Pichler, M. Mitterhauser, L. Pezawas and N. Praschak-Rieder have no conflict of interest to declare. Publisher Copyright: {\textcopyright} 2021 The Author(s) Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",
year = "2021",
doi = "10.1016/j.nicl.2021.102813",
language = "English",
volume = "32",
journal = "NeuroImage: Clinical",
issn = "2213-1582",
}